The study used large-scale CRISPR gene-editing technology to systematically determine which genes are required as embryonic ...

Can gene editing truly support smallholder farmers and help Indonesia achieve food sovereignty, or will it simply revive the ...

Ascidian Therapeutics ("Ascidian"), a biotechnology company seeking to treat human diseases by rewriting RNA, and Forge ...

Ascidian Therapeutics and Forge Biologics have partnered to advance the development and manufacturing of ACDN-01.

Researchers suggest that they have recovered sequences from ancient works and letters that may belong to the Renaissance ...

Team from Würzburg, Braunschweig, and the US identifies Cas12a3 nuclease showing precise activity | Study just published in Nature ...

Texas A&M AgriLife faculty, staff and graduate students earn Vice Chancellor’s Awards in Excellence honors at Texas A&M ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $496.45, a high estimate of $564.00, and a low estimate of $414.00. Witnessing a positive shift, the ...

The technology, called the Viral-Engineered RNA-based Activation System (VERAS), hijacks the virus's own replication ...

Regeneron Pharmaceuticals (NASDAQ: REGN) underwent analysis by 21 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.

GEN’s first virtual event of 2026—we present a group of outstanding researchers and thought-leaders to discuss the latest advances and challenges in delivering genetic therapies.

An analysis of genetic data from over 900,000 people shows that certain stretches of DNA, made up of short sequences repeated ...